Skip to main navigation menu Skip to main content Skip to site footer

Original article

Vol. 148 No. 3334 (2018)

Cardiac Resynchronisation Therapy (CRT) Survey II: CRT implantation in Europe and in Switzerland

  • Ivan Zeljkovic
  • Haran Burri
  • Alexander Breitenstein
  • Peter Ammann
  • Andreas Mueller
  • Angelo Auricchio
  • Etienne Delacrétaz
  • Kenneth Dickstein
  • Cecilia Linde
  • Camilla Normand
  • Christian Sticherling
Cite this as:
Swiss Med Wkly. 2018;148:w14643


AIM: Between October 2015 and December 2016, 11,088 patients from 42 countries having cardiac resynchronisation therapy (CRT) devices implanted were included in the CRT II Survey. We compared the characteristics of Swiss CRT recipients with the overall European population.


Demographic and procedural data from seven Swiss centres recruiting all consecutive patients undergoing either de-novo CRT implantation or an upgrade to a CRT system were collected and compared with the European population.


A total of 320 Swiss patients (24.4% female, mean age 71.0 ± 10.2 years, 47% ischaemic cardiomyopathy) were enrolled, which amounts to 38% of all CRT implantations in Switzerland during this period. Of the patients enrolled, 38% had atrial fibrillation, 27% second- or third-degree atrioventricular block, and 68% complete left bundle-branch block. Swiss patients had significantly less often the classical indication of heart failure with a wide QRS complex (40 vs 61%; odds ratio [OR] 0.44, 95% confidence interval [CI] 0.35–0.55; p <0.001). Compared with the European population, Swiss patients were significantly older (71 vs 68.5 years, p <0.001), less symptomatic from heart failure and had more chronic kidney disease. Swiss patients significantly more often received a CRT-pacemaker (37 vs 30%; OR 1.37; 95% CI 1.09–1.73; p = 0.007) and quadripolar left ventricular leads (69 vs 57%; OR 1.67, 95% CI 1.32–2.13; p <0.001).

CONCLUSION: Compared with European CRT recipients, Swiss CRT patients are older, less symptomatic and suffer more often from comorbidities. Although two thirds of the implantations were CRT-defibrillator systems, Swiss patients more often received CRT-pacemaker systems than their European counterparts.


  1. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, et al.; Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352(15):1539–49. doi:.
  2. Tang AS, Wells GA, Talajic M, Arnold MO, Sheldon R, Connolly S, et al.; Resynchronization-Defibrillation for Ambulatory Heart Failure Trial Investigators. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med. 2010;363(25):2385–95. doi:.
  3. Bogale N, Priori S, Cleland JG, Brugada J, Linde C, Auricchio A, et al.; Scientific Committee, National Coordinators, and Investigators. The European CRT Survey: 1 year (9-15 months) follow-up results. Eur J Heart Fail. 2012;14(1):61–73. doi:.
  4. Gitt AK, Bueno H, Danchin N, Fox K, Hochadel M, Kearney P, et al. The role of cardiac registries in evidence-based medicine. Eur Heart J. 2010;31(5):525–9. doi:.
  5. Masoudi FA, Havranek EP, Wolfe P, Gross CP, Rathore SS, Steiner JF, et al. Most hospitalized older persons do not meet the enrollment criteria for clinical trials in heart failure. Am Heart J. 2003;146(2):250–7. doi:.
  6. Dickstein K, Bogale N, Priori S, Auricchio A, Cleland JG, Gitt A, et al.; Scientific Committee; National Coordinators. The European cardiac resynchronization therapy survey. Eur Heart J. 2009;30(20):2450–60. doi:.
  7. Dickstein K, Normand C, Anker SD, Auricchio A, Blomström CL, Bogale N, et al. European cardiac resynchronization therapy survey II: rationale and design. Europace. 2015;17(1):137–41. doi:.
  8. Dickstein K, Normand C, Auricchio A, Bogale N, Cleland JG, Gitt AK, et al.; Scientific Committee, National Coordinators, and Investigators. CRT Survey II: a European Society of Cardiology survey of cardiac resynchronisation therapy in 11 088 patients-who is doing what to whom and how? Eur J Heart Fail. 2018;20(6):1039–51. doi:.
  9. (last accessed 8 February 2018)
  10. Køber L, Thune JJ, Nielsen JC, Haarbo J, Videbæk L, Korup E, et al.; DANISH Investigators. Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure. N Engl J Med. 2016;375(13):1221–30. doi:.
  11. Schaer B, Frey S, Sticherling C, Osswald S, Reichlin T, Kühne M. Persistent improvement of ejection fraction in patients with a cardiac resynchronisation therapy defibrillator correlates with fewer appropriate ICD interventions and lower mortality. Swiss Med Wkly. 2016;146:w14300. doi:.
  12. Bossard M, Sticherling C, Kühne M, Frey S, Osswald S, Schaer B. Outcome of patients with cardiac resynchronisation defibrillator therapy and a follow-up of at least five years after implant. Swiss Med Wkly. 2014;144:w13938. doi:.
  13. Schaer B, Theuns DA, Sticherling C, Szili-Torok T, Osswald S, Jordaens L. Effect of implantable cardioverter-defibrillator on left ventricular ejection fraction in patients with idiopathic dilated cardiomyopathy. Am J Cardiol. 2010;106(11):1640–5. doi:.
  14. Bansal N, Szpiro A, Reynolds K, Smith DH, Magid DJ, Gurwitz JH, et al. Long-term Outcomes Associated With Implantable Cardioverter Defibrillator in Adults With Chronic Kidney Disease. JAMA Intern Med. 2018;178(3):390–8. doi:.
  15. Schaer BA, Hitz L, Sticherling C, Kühne M, Dickenmann M, Jordaens L, et al. Changes in renal function over time in patients with cardiac resynchronisation therapy. Swiss Med Wkly. 2013;143:w13863. doi:.
  16. Hindricks G, Camm AJ, Merkely B, Raatikainen P, Arnar DO. The EHRA White Book 2016. 2016; (last accessed February 2018).
  17. Linde C, Abraham WT, Gold MR, St John Sutton M, Ghio S, Daubert C ; REVERSE (REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction) Study Group. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J Am Coll Cardiol. 2008;52(23):1834–43. doi:.
  18. Sticherling C, Arendacka B, Svendsen JH, Wijers S, Friede T, Stockinger J, et al.; EU-CERT-ICD Investigators. Sex differences in outcomes of primary prevention implantable cardioverter defibrillator therapy: combined registry data from eleven European countries. Europace. 2018;20(6):963–70. doi:.
  19. Brignole M, Auricchio A, Baron-Esquivias G, Bordachar P, Boriani G, Breithardt OA, et al.; European Society of Cardiology (ESC); European Heart Rhythm Association (EHRA). 2013 ESC guidelines on cardiac pacing and cardiac resynchronization therapy: the task force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Europace. 2013;15(8):1070–118. doi:.
  20. Bogale N, Priori S, Gitt A, Alings M, Linde C, Dickstein K, et al.; Scientific Committee, National coordinators, and investigators. The European cardiac resynchronization therapy survey: patient selection and implantation practice vary according to centre volume. Europace. 2011;13(10):1445–53. doi:.
  21. Winnik S, Elsener C, Seifert B, Starck C, Straub A, Saguner AM, et al. “Real world” experience in Cardiac Resynchronization Therapy at a Swiss Tertiary Care Center. Swiss Med Wkly. 2017;147:w14425. doi:.
  22. Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, et al.; ESC Scientific Document Group; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018;39(3):213–60. doi:.

Most read articles by the same author(s)

1 2 3 > >>